TipRanks
Advertisement
Advertisement

ROIV Stock Latest News

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
The FlyWainwright maintains confidence in Immunovant’s pipeline despite CLE setback
3d ago
IMVT
ROIV
Roivant Sciences price target raised to $41 from $37.50 at BofA
PremiumThe Fly
Roivant Sciences price target raised to $41 from $37.50 at BofA
3d ago
IMVT
ROIV
Roivant announces trial of IMVT-1402 did not reach statistical significance
PremiumThe Fly
Roivant announces trial of IMVT-1402 did not reach statistical significance
3d ago
ROIV
Roivant Shareholders Approve Directors and Governance Matters
PremiumCompany Announcements
Roivant Shareholders Approve Directors and Governance Matters
8d ago
8K
ROIV
Roivant Sciences initiated with a Buy at Stifel
PremiumThe Fly
Roivant Sciences initiated with a Buy at Stifel
10d ago
ROIV
Roivant Sciences price target raised to $55 from $50 at TD Cowen
PremiumThe FlyRoivant Sciences price target raised to $55 from $50 at TD Cowen
17d ago
ROIV
Roivant Sciences price target raised to $46 from $42 at Guggenheim
Premium
The Fly
Roivant Sciences price target raised to $46 from $42 at Guggenheim
17d ago
ROIV
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
Premium
The Fly
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
18d ago
ROIV
Roivant Sciences rises 18.9%
PremiumThe Fly
Roivant Sciences rises 18.9%
18d ago
ROIV
Midday Fly By: Amazon dominates headlines with Qualcomm pact, cargo flight crash
PremiumThe Fly
Midday Fly By: Amazon dominates headlines with Qualcomm pact, cargo flight crash
18d ago
GE
ABM
Roivant Sciences price target raised to $52 from $42 at Jefferies
PremiumThe Fly
Roivant Sciences price target raised to $52 from $42 at Jefferies
18d ago
ROIV
Roivant Sciences rises 17.6%
PremiumThe Fly
Roivant Sciences rises 17.6%
18d ago
ROIV
Roivant advances mosliciguat with positive Phase 2 results
PremiumCompany AnnouncementsRoivant advances mosliciguat with positive Phase 2 results
18d ago
8K
ROIV
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint
Premium
The Fly
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint
18d ago
BSX
HLF
Roivant Sciences up 21% to $42.50 after Phase 2 PHocus trial met endpoint
Premium
The Fly
Roivant Sciences up 21% to $42.50 after Phase 2 PHocus trial met endpoint
18d ago
ROIV
Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial
PremiumThe Fly
Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial
18d ago
ROIV
Lisraya Pricing Upside and Measured Launch Drive Modest Roivant Target Increase to $37.50, Supporting Hold Rating Amid Balanced Risk/Reward
PremiumRatings
Lisraya Pricing Upside and Measured Launch Drive Modest Roivant Target Increase to $37.50, Supporting Hold Rating Amid Balanced Risk/Reward
26d ago
ROIV
Roivant wins FDA nod for LISRAYA dermatomyositis therapy
PremiumCompany Announcements
Roivant wins FDA nod for LISRAYA dermatomyositis therapy
29d ago
8K
ROIV
Douglas Tsao Reiterates Buy on Lisraya Maker, Citing Strong VALOR Data and Steroid-Sparing Profile; Maintains $41 Price Target
PremiumRatings
Douglas Tsao Reiterates Buy on Lisraya Maker, Citing Strong VALOR Data and Steroid-Sparing Profile; Maintains $41 Price Target
29d ago
ROIV
Roivant Gains FDA Approval for LISRAYA Dermatomyositis Therapy
PremiumCompany AnnouncementsRoivant Gains FDA Approval for LISRAYA Dermatomyositis Therapy
30d ago
8K
ROIV
Priovant Therapeutics announces FDA approval of Lisraya
Premium
The Fly
Priovant Therapeutics announces FDA approval of Lisraya
30d ago
ROIV
Roivant Sciences Earnings Call: Cash-Rich, Catalyst-Heavy
Premium
Company Announcements
Roivant Sciences Earnings Call: Cash-Rich, Catalyst-Heavy
1M ago
ROIV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >